New Safety Information for Tarceva (erlotinib)
May 9th, 2009 | 
Author: FDA MedWatch Alert
New Safety Information for Tarceva (erlotinib)
May 8, 2009
Audience: Oncological, dermatological and ophthalmological healthcare professionals.
OSI, Genentech and FDA notified healthcare professionals of new safety information added to the WARNINGS AND PRECAUTIONS sections of the prescribing information for Tarceva. Gastrointestinal perforation (including fatalities), bullous, blistering and exfoliative skin conditions including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, in some cases fatal, and ocular disorders…
Related posts:
- FDA Approves Updated Labeling for Antiepileptic Drugs FDA MedWatch Alert FDA Approves Updated Labeling for Antiepileptic Drugs...
Related posts brought to you by Yet Another Related Posts Plugin.
Posted in FDA Alerts
